We found a multicentre, open-label, non-randomised phase 1b/2a study on autologous RNA CAR T cells and some case reports on single-target (CD19 or BCMA) CAR T cells in myasthenia gravis. This evidence concerns the gene CD19 and myasthenia gravis.